GLP-1 Metabolic Weight Programme

Medically supervised GLP-1 receptor agonist therapy (Ozempic, Wegovy, Saxenda) integrated within a structured weight and metabolic health programme, combining pharmacological appetite regulation with clinical monitoring and lifestyle support.

GLP-1 receptor agonists (GLP-1 RAs) have transformed the clinical management of obesity and metabolic dysfunction. These medications — including semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) — mimic the action of a natural gut hormone (glucagon-like peptide-1) to regulate appetite, slow gastric emptying, and improve insulin sensitivity. Clinical trials have demonstrated sustained weight loss of 10–20% body weight in patients using semaglutide, alongside significant improvements in cardiometabolic risk markers. At HMI Medical, GLP-1 therapy is never prescribed in isolation. It is available only to patients who have completed the Weight & Metabolic Health Assessment and received a clinical recommendation from one of HMI's weight management physicians. This gatekeeping reflects responsible prescribing: GLP-1 agents are potent medications with side-effect profiles and contraindications that require proper clinical screening. For appropriate candidates, the GLP-1 programme operates within the structured Weight Care Programme framework. Patients begin on a low dose that is titrated upward over 4–12 weeks to an effective maintenance dose, with nurse monitoring appointments to track tolerability, weight trajectory, and metabolic markers. Regular physician reviews allow dose adjustments and assessment of ongoing response. HMI Medical's programme is designed for long-term metabolic health improvement, not rapid cosmetic weight loss. The clinical team provides education on lifestyle optimisation — nutrition, activity, sleep, stress management — to maximise the durability of outcomes and facilitate a planned, evidence-based approach to eventual medication tapering where appropriate.